Navigation Links
Biodel to Raise $30 Million Through Registered Direct Offering
Date:5/13/2011

DANBURY, Conn., May 13, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that it has entered into definitive agreements with a group of institutional investors, including Great Point Partners, LLC and Orbimed Advisors, LLC, to sell approximately 12.2 million shares of its common stock, 1.7 million shares of its Series A Convertible Preferred Stock and warrants to purchase 9.0 million shares of its common stock.  These securities are being sold as units, with each unit consisting of one share of common stock and a warrant to purchase 0.65 of a share of common stock.  However, certain investors are also purchasing units that consist of one share of Series A Convertible Preferred stock and a warrant to purchase 0.65 of a share of common stock in addition to the units comprised of common stock and a warrant to purchase 0.65 of a share of common stock.  The Series A Convertible Preferred Stock is non-voting.  Each share of Series A Convertible Preferred Stock is convertible into one share of Biodel's common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.98% of the total number of Biodel shares of common stock outstanding following conversion.

The investors have agreed to purchase the units for a negotiated price of $2.16 per unit, resulting in gross proceeds to Biodel, before deducting placement agents' fees and estimated offering expenses, of approximately $30 million.  The offering is expected to close on or about May 18, 2011, subject to customary closing conditions.  William Blair & Company, L.L.C. acted as sole lead placement agent for the offering and JMP Securities LLC acted as co-placement agent.

The per share exercise price of the warrants is $2.48.  The warrants will be exercisable beginning on the original date of issuance and will expire on the date that is five years after the original issuance date.

Biodel has filed a registration statement (including a prospectus) with the SEC for the securities offering described in this communication.  Before you invest, you should read the prospectus in that registration statement and other documents Biodel has filed with the SEC for more complete information about Biodel and this offering.  You may obtain these documents free of charge by visiting EDGAR on the SEC's website at www.sec.gov.  Alternatively, copies of the prospectus meeting the requirements of Section 10 of the Securities Act of 1933 may be obtained by contacting William Blair & Company, L.L.C., 222 West Adams Street, Chicago, IL 60606, attention: Equity Capital Markets, telephone 312-236-1600, or JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, CA 94111, attention: Equity Capital Markets, telephone 415-835-8900.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients.  Biodel develops its product candidates by applying its proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's expectations related to the closing of the offering. Forward-looking statements represent our management's judgment regarding future events.  The Company's forward-looking statements are subject to a number of known and unknown risks and uncertainties, many of which are beyond its control, including risks related to closing of the contemplated offering, that could cause actual results, performance or achievements to differ materially from those described in the forward- looking statements.  For additional disclosure regarding these and other risks faced by Biodel, see the disclosure contained in its public filings with the SEC available on the SEC's website at www.sec.gov.  These forward-looking statements represent the Company's views only as of the date they are made and should not be relied upon as representing its views as of any subsequent date.  The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT: Seth Lewis, +1-646-378-2952


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biodel Announces Name Change for Lead Product Candidate
2. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
3. Bacon Eating Contest Raises Money for American Heart Association
4. Proteolix Raises $79 Million in Series C Financing
5. Yongye Biotechnology International Raises $9.4 Million in Private Placement
6. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
7. MacroGenics Raises $25M in Series D-2 Financing
8. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income
9. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
10. California State Senator Shelia Kuehls Leadership in Stem Cell Debate Praised and Embryonic Stem Cell Profiteers Criticized by Repair Stem Cell Institute Spokesman
11. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.65
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MD (PRWEB) , ... April 20, 2017 , ... ... the formation of a unique intellectual property (IP) sharing and commercialization model. , ... most promising inventions. A main component of this effort is bringing the IP ...
(Date:4/20/2017)... YORK , April 20, 2017 ... that focuses on novel drug development and clinical research aimed ... are: Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), ... ZIOP ). You can access our complimentary research ... ...
(Date:4/19/2017)... , ... April 18, 2017 , ... Alisa Wright, founder ... Alumni Awards from the Purdue College of Pharmacy in Lafayette, Indiana. , The ... Program for achievements in their careers and other scientific endeavors. , Wright began ...
(Date:4/19/2017)... (PRWEB) , ... April 19, 2017 , ... ... $1.5M Series A-1 financing round. This event adds to several other early achievements ... its’ Executive and Scientific Teams. , ThermaGenix will use proceeds from ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):